Denali Therapeutics
Biology Discovery
Dr. Logan received his B.S. in Brain and Cognitive Sciences from MIT and his Ph.D in Biomedical Sciences at UCSF, where he studied the physiological role of alpha-synuclein in the regulation of exocytosis. Since then, Dr. Logan has spent the past 5+ years at Denali Therapeutics, where his primary focus has been to elucidate the molecular mechanisms underlying pathogenesis of progranulin loss-of-function in Frontotemporal Dementia (FTD).

Moderator of 1 Session

Session Type
SYMPOSIUM
Date
Fri, 18.03.2022
Session Time
09:10 AM - 10:55 AM
Room
ONSITE: 113

Presenter of 1 Presentation

RESCUE OF A LYSOSOMAL STORAGE DISORDER CAUSED BY GRN LOSS-OF-FUNCTION WITH A BRAIN PENETRANT PROGRANULIN BIOLOGIC

Session Type
SYMPOSIUM
Date
Fri, 18.03.2022
Session Time
09:10 AM - 10:55 AM
Room
ONSITE: 113
Lecture Time
09:55 AM - 10:10 AM

Abstract

Aims

GRN mutations cause frontotemporal dementia (GRN-FTD) due to deficiency in progranulin (PGRN), a lysosomal and secreted protein with unclear function.

Methods

We utilized targeted lipidomic profiling to characterize changes in lysosomal lipids in the brain of Grn-/- mouse as well as in GRN-FTD patient CSF and plasma samples. Further, we investigated a protein replacement strategy by engineering protein transport vehicle (PTV):PGRN—a recombinant protein linking PGRN to a modified Fc domain that binds human transferrin receptor for enhanced CNS biodistribution.

Results

Here, we found that Grn–/– mice exhibit a global deficiency in bis(monoacylglycero)phosphate (BMP), an endolysosomal phospholipid we identified as a pH-dependent PGRN interactor as well as a redox-sensitive enhancer of lysosomal proteolysis and lipolysis. Grn–/– brains also showed an age-dependent, secondary storage of glucocerebrosidase substrate glucosylsphingosine. PTV:PGRN rescued various Grn–/– phenotypes in primary murine macrophages and hu- man iPSC-derived microglia, including oxidative stress, lysosomal dysfunction, and endomembrane damage. Peripherally delivered PTV:PGRN corrected levels of BMP, glucosylsphingosine, and disease pathology in Grn–/– CNS, including microgliosis, lipofuscinosis, and neuronal damage.

Conclusions

PTV:PGRN thus represents a potential biotherapeutic for GRN-FTD.

Hide